Celldex Therapeutics, Inc.
CLDX
$30.29
$1.756.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.29% | -18.45% | -5.21% | -14.24% | -11.80% |
| Total Depreciation and Amortization | -0.97% | -5.61% | 0.69% | 5.86% | 4.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.06% | 3.78% | 6.41% | 9.84% | 21.36% |
| Change in Net Operating Assets | -12.95% | 132.46% | 149.64% | -215.18% | 138.23% |
| Cash from Operations | -31.49% | -10.51% | 19.07% | -67.42% | 41.31% |
| Capital Expenditure | -191.14% | 39.56% | -174.72% | 64.95% | -38.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.47% | 21.17% | 17.04% | 74.23% | -48.65% |
| Cash from Investing | -8.91% | 22.06% | 16.07% | 78.61% | -49.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.29% | 1,128.57% | -68.81% | -47.67% | -68.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 74.29% | 1,128.57% | -68.81% | -47.67% | -68.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.15% | 119.92% | 152.66% | -39.50% | -26.86% |